ACRV Acrivon Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1781174 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY14.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-74.1%
ROA-64.0%
ROIC (approx.)-104.8%
Asset turnover—
Leverage & solvency
Liabilities / assets17.5%
Debt / equity0.00x
Current ratio5.54x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $59.99M | $63.99M |
| SG&A expense | $24.12M | $25.21M |
| Operating income | -$84.11M | -$89.20M |
| Pretax income | -$77.83M | -$80.44M |
| Income tax | $0 | — |
| Net income | -$77.91M | -$80.56M |
| EBITDA | -$82.76M | -$88.19M |
| EPS (basic) | -2.02 | -2.38 |
| EPS (diluted) | -2.02 | -2.38 |
| Weighted avg. shares (diluted) | 38.51M | 33.79M |
| Balance sheet | ||
| Cash & equivalents | $41.50M | $39.82M |
| Short-term investments | $77.08M | $139.66M |
| Current assets | $120.44M | $181.63M |
| PP&E, net | $4.89M | $4.47M |
| Total assets | $129.72M | $196.59M |
| Current liabilities | $15.66M | $17.21M |
| Total liabilities | $17.20M | $19.80M |
| Shareholders' equity | $112.52M | $176.79M |
| Shares outstanding | 31.65M | 31.23M |
| Cash flow statement | ||
| Operating cash flow | -$63.66M | -$65.67M |
| Capital expenditure | $1.67M | $2.77M |
| Free cash flow | -$65.33M | -$68.44M |
| Investing cash flow | $66.10M | -$51.77M |
| Financing cash flow | -$749,000 | $121.03M |
| Depreciation & amortization | $1.36M | $1.01M |
| Stock-based compensation | $14.72M | $14.29M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.